Citi Bolsters Healthcare Investment Banking Team- #CapitalMarkets #Finance #Treasury #Finance

Why It Matters

By adding a proven dealmaker, Citi enhances its ability to capture high‑value healthcare mandates in the fast‑growing ANZ market, reinforcing its leadership in global healthcare investment banking.

Key Takeaways

• Citi hires former Goldman Sachs healthcare head for ANZ
• Bartholomaeus led A$1.6bn DBG Health investment deal
• Citi aims to expand APAC healthcare advisory capabilities
• Bank already top global healthcare M&A adviser 2024‑2026
• New hires reinforce Citi's APAC pipeline and client service

Pulse Analysis

The Asia‑Pacific healthcare sector is experiencing a surge of capital as governments and private investors pour funds into biopharma, med‑tech and diagnostics. Citi has leveraged this momentum to become the leading global adviser on healthcare M&A from 2024 through 2026, steering transactions that total over $70 billion. This dominance is anchored in the bank’s extensive cross‑border network, deep sector research, and a growing roster of specialists who can navigate complex regulatory environments across Australia, New Zealand and the broader region.

Ben Bartholomaeus arrives with a track record that aligns perfectly with Citi’s growth agenda. At Goldman Sachs, he orchestrated the A$1.6 billion DBG Health investment and facilitated the sale of a major stake in Novotech to sovereign investors GIC and Temasek, showcasing his ability to close large‑scale, multi‑party deals. Based in Sydney, he will report to both the local capital‑markets co‑heads and the APAC healthcare head, ensuring that global resources are seamlessly integrated with regional client relationships.

The appointment sends a clear signal to Australian and New Zealand healthcare companies that Citi is deepening its advisory bench to capture the next wave of mergers, acquisitions and capital‑raising activities. Competitors such as JPMorgan and Bank of America will need to match this talent push to remain relevant in a market where deal volume is projected to outpace global averages. For investors, Citi’s reinforced platform promises more sophisticated execution, broader financing options, and heightened confidence in navigating the increasingly competitive healthcare landscape.